(19)
(11) EP 3 668 972 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
13.11.2024 Bulletin 2024/46

(45) Mention of the grant of the patent:
09.10.2024 Bulletin 2024/41

(21) Application number: 18846060.4

(22) Date of filing: 20.08.2018
(51) International Patent Classification (IPC): 
C12N 9/22(2006.01)
A61K 38/46(2006.01)
(52) Cooperative Patent Classification (CPC):
C12N 9/22; C12Y 301/21001; C07K 2319/02; C07K 2319/31; C07K 2319/80; C07K 2319/91; A61K 38/00
(86) International application number:
PCT/US2018/047084
(87) International publication number:
WO 2019/036719 (21.02.2019 Gazette 2019/08)

(54)

ENGINEERED DNASE ENZYMES AND USE IN THERAPY

KONSTRUIERTE DNASE-ENZYME UND IHRE VERWENDUNG IN DER THERAPIE

ENZYMES DNASE GÉNÉTIQUEMENT MODIFIÉES ET LEUR UTILISATION EN THÉRAPIE


(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 18.08.2017 US 201762547220 P
28.12.2017 US 201762611166 P

(43) Date of publication of application:
24.06.2020 Bulletin 2020/26

(60) Divisional application:
24205258.7

(73) Proprietor: Neutrolis, Inc.
Cambridge, MA 02142 (US)

(72) Inventors:
  • FUCHS, Tobias A.
    Cambridge, MA 02139 (US)
  • JIMÉNEZ-ALCÁZAR, Miguel
    Cambridge, MA 02139 (US)
  • GÖBEL, Josephine (formerly BITTERLING, Josephine)
    Cambridge, MA 02139 (US)
  • ENGLERT, Hanna
    Cambridge, MA 02139 (US)

(74) Representative: Grund, Martin et al
Grund Intellectual Property Group Patentanwälte und Solicitor PartG mbB Steinsdorfstraße 2
80538 München
80538 München (DE)


(56) References cited: : 
WO-A2-2011/053982
US-A1- 2016 376 366
US-A1- 2009 010 966
   
  • ANDREW WILBER ET AL: "Deoxyribonuclease 1-like III is an inducible macrophage barrier to liposomal transfection", MOLECULAR THERAPY, NO LONGER PUBLISHED BY ELSEVIER, vol. 6, no. 1, 1 July 2002 (2002-07-01), pages 35 - 42, XP002641392, ISSN: 1525-0016, DOI: 10.1006/MTHE.2002.0625
  • JIMÉNEZ-ALCÁZAR M ET AL: "Impaired DNase1-mediated degradation of neutrophil extracellular traps is associated with acute thrombotic microangiopathies", JOURNAL OF THROMBOSIS AND HAEMOSTASIS, vol. 13, no. 5, 13 April 2015 (2015-04-13), pages 732 - 742, XP055782172, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pubmed/25418346> DOI: 10.1111/jth.12796
  • SISIRAK VANJA ET AL: "Digestion of Chromatin in Apoptotic Cell Microparticles Prevents Autoimmunity", CELL, ELSEVIER, AMSTERDAM NL, vol. 166, no. 1, 9 June 2016 (2016-06-09), pages 88 - 101, XP029627879, ISSN: 0092-8674, DOI: 10.1016/J.CELL.2016.05.034
  • SHIOKAWA DAISUKE ET AL: "Identification of two functional nuclear localization signals in DNase [gamma] and their roles in its apoptotic DNase activity", BIOCHEMICAL JOURNAL, vol. 376, no. 2, 1 December 2003 (2003-12-01), pages 377 - 381, XP055782937, ISSN: 0264-6021, Retrieved from the Internet <URL:http://portlandpress.com/biochemj/article-pdf/376/2/377/712183/bj3760377.pdf> DOI: 10.1042/bj20030820
  • JIMÉNEZ-ALCÁZAR MIGUEL ET AL: "Host DNases prevent vascular occlusion by neutrophil extracellular traps", SCIENCE, vol. 358, no. 6367, 1 December 2017 (2017-12-01), US, pages 1202 - 1206, XP055783049, ISSN: 0036-8075, DOI: 10.1126/science.aam8897
  • MONA SAFFARZADEH ET AL: "Fighting against the dark side of neutrophil extracellular traps in disease : manoeuvres for host protection", CURRENT OPINION IN HEMATOLOGY, vol. 20, no. 1, 1 January 2013 (2013-01-01), US, pages 3 - 9, XP055471240, ISSN: 1065-6251, DOI: 10.1097/MOH.0b013e32835a0025
  • JORCH SELINA K ET AL: "An emerging role for neutrophil extracellular traps in noninfectious disease", NATURE MEDICINE, vol. 23, no. 3, 1 March 2017 (2017-03-01), New York, pages 279 - 287, XP055785209, ISSN: 1078-8956, Retrieved from the Internet <URL:http://www.nature.com/articles/nm.4294> DOI: 10.1038/nm.4294
  • DABROWSKA D ET AL: "New Aspects of the Biology of Neutrophil Extracellular Traps.", SCANDINAVIAN JOURNAL OF IMMUNOLOGY DEC 2016, vol. 84, no. 6, December 2016 (2016-12-01), pages 317 - 322, ISSN: 1365-3083
  • BRINKMANN VOLKER ET AL: "Neutrophil extracellular traps kill bacteria", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, vol. 303, no. 5663, 5 March 2004 (2004-03-05), pages 1532 - 1535, XP002469080, ISSN: 0036-8075, DOI: 10.1126/SCIENCE.1092385
  • KOBAYASHI, Y ET AL.: "Synchronous growth of Pichia Pastoris for a high rate production of Dnasel ata microquantities", THE 10TH APCCHE CONGRESS THE ASIAN PACIFIC CONFEDERATION OF CHEMICAL ENGINEERING : CONFERENCE PROCEEDINGS : OCTOBER 17-21, 2004 KITAKYUSHU, JAPAN, no. 833, 1 January 2004 (2004-01-01), pages 1 - 6, XP055679026, DOI: 10.11491/apcche.2004.0.953.0
  • HAKKIM, ABDUL ET AL.: "Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES , vol. 107, no. 21, May 2010 (2010-05-01), pages 9813 - 9818, XP0002592735, DOI: 10.1073/pnas0909927107
  • PICCOLO, F ET AL.: "Intrapleural Tissue Plasminogen Activator and Deoxyribonuclease for Pleural Infection. An Effective and Safe Alternative to Surgery", ANNALS ATS, vol. 11, no. 9, November 2014 (2014-11-01), pages 1419 - 1425, XP055678828, DOI: 10.1513/AnnalsATS.201407-329OC
  • PERINI ET AL: "Topical application of Acheflan on rat skin injury accelerates wound healing: a histopathological, immunohistochemical and biochemical study", BMC COMPLEMENTARY MEDICINE AND THERAPIES, vol. 15, 203, 30 June 2015 (2015-06-30), XP055678836, DOI: 10.1186/s12906-015-0745x
  • ANDREW WILBUR ET AL: "Deoxyribonuclease I-like III Is an Inducible Macrophage Barrier to Liposomal Transfection", MOLECULAR THERAPY, vol. 6, no. 1, 2002, pages 35 - 42, XP002641392, DOI: 10.1006/mthe.2002.0625
  • BERNTSSON RP. ET AL.: "Structural insight into DNA binding and oligomerization of the multifunctional Cox protein of bacteriophage P2.", NUCLEIC ACIDS RESEARCH, vol. 42, no. 4, 23 November 2013 (2013-11-23), pages 2725 - 2735, XP055678852, DOI: 10.1093/nar/gkt1119
 
Remarks:
The file contains technical information submitted after the application was filed and not included in this specification
 
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).